Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Labetalol is a competitive antagonist at both beta-adrenoceptors (beta1 and beta2) and alpha1-adrenoceptors, leading to decreased cardiac output, peripheral vascular resistance, and reduced blood pressure.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Hypertension (FDA-approved),Hypertensive emergency (off-label),Pregnancy-induced hypertension (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous: Initially 20 mg (0.25 mg/kg for 70 kg) over 2 minutes, then 40-80 mg every 10 minutes until desired response or total 300 mg; or continuous infusion at 0.5-2 mg/min titrated to blood pressure. Switch to oral when stable.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is 6-8 hours; may be prolonged in elderly, hepatic impairment, or renal impairment (up to 16 hours).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Extensively metabolized in the liver via glucuronidation (direct conjugation) and also via CYP2D6 (minor pathway).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (90-95% as unchanged drug and glucuronide conjugates) and a small amount in feces (<5%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 50% bound to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Vd is 0.5-1.2 L/kg; distributes extensively into tissues, including crossing the placenta and entering breast milk.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: 25-40% due to extensive first-pass metabolism; Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific dose adjustment required for GFR >15 m L/min; for GFR <15 m L/min or dialysis, use with caution and consider reducing dose. Monitor for hypotension and bradycardia.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: No adjustment required. Child-Pugh B: Reduce dose by 50% and titrate slowly. Child-Pugh C: Contraindicated due to extensive hepatic metabolism.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous: 0.2-0.5 mg/kg/dose every 10 minutes as needed, up to 1 mg/kg total. Continuous infusion: 0.25-3 mg/kg/hour. Maximum single dose: 1 mg/kg.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start with low end of dosing range (e.g., 10-20 mg IV initial), titrate cautiously due to increased sensitivity and risk of hypotension, bradycardia, and bronchospasm.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA boxed warning.
None.
May cause bronchospasm in patients with asthma/COPD; may mask symptoms of hypoglycemia or thyrotoxicosis; may cause severe bradycardia; discontinue if signs of hepatic injury occur; use caution in patients with heart failure or diabetes.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to labetalol; bronchial asthma; overt cardiac failure; cardiogenic shock; severe bradycardia; heart block greater than first degree; severe hypotension.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid alcohol, which can enhance hypotensive and sedative effects. No significant food interactions are documented, but a balanced diet is recommended. Maintain adequate fluid intake to prevent dehydration-induced hypotension.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Limited human data; animal studies show no major teratogenic effects at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, hypotension, hypoglycemia, and intrauterine growth restriction due to beta-blockade. Risk of preterm delivery and respiratory depression at birth.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted into breast milk in small amounts; average milk-to-plasma ratio (M/P) 0.15-0.80. Considered compatible with breastfeeding by American Academy of Pediatrics, but monitor infant for bradycardia and hypotension.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may increase clearance and volume of distribution, potentially requiring dose escalation. However, dose adjustments should be guided by clinical response and tolerability. Start at lowest effective dose and titrate carefully. No standard dose adjustment recommended; individualize based on maternal blood pressure and fetal well-being.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Labetalol combines alpha-1 and non-selective beta-blockade, causing less reflex tachycardia than pure beta-blockers. It is a pregnancy category C drug but is commonly used for hypertensive emergencies in pregnancy (e.g., preeclampsia). Monitor for orthostatic hypotension, especially during IV administration. Avoid in patients with bronchial asthma, heart block, or severe bradycardia. May mask symptoms of hypoglycemia and thyrotoxicosis.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Do not stop taking this medication suddenly; abrupt withdrawal may worsen chest pain or cause a heart attack.,This drug may cause dizziness or lightheadedness, especially when standing up quickly; rise slowly from sitting or lying down.,Avoid alcohol, as it may increase dizziness and drowsiness.,Inform all healthcare providers that you are taking labetalol, especially before surgery or dental procedures.,If you have diabetes, monitor blood sugar closely, as labetalol can mask signs of low blood sugar.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Labetalol, a non-selective beta-blocker with additional alpha-1 blocking activity, may augment the vasodilatory effects of epoprostenol, a prostacyclin analog used for pulmonary arterial hypertension. This additive hypotensive effect can lead to symptomatic hypotension, dizziness, syncope, or compromised organ perfusion, particularly during dose titration of either agent. Close hemodynamic monitoring is warranted to prevent adverse outcomes."
"Phenelzine, a nonselective monoamine oxidase inhibitor (MAOI), increases norepinephrine and epinephrine stores in sympathetic nerve terminals. Labetalol, a nonselective beta-blocker with alpha-1 blocking activity, normally can be taken up by adrenergic neurons; however, in the presence of MAOIs, labetalol may cause a hypertensive response due to unopposed alpha-adrenergic activity from accumulated catecholamines. This can lead to an exaggerated increase in blood pressure instead of the intended hypotensive effect, posing a risk of hypertensive crisis."
"Labetalol, a non-selective beta-blocker with additional alpha-1 blocking activity, may antagonize the antihypertensive effects of azelastine, an H1-antihistamine that also has mild vasodilatory properties. Beta-blockers like labetalol can blunt compensatory sympathetic responses and reduce cardiac output, potentially counteracting azelastine's ability to lower blood pressure. This interaction may lead to diminished antihypertensive efficacy and require dose adjustments or alternative therapy."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is a Electrolyte that works by Labetalol is a competitive antagonist at both beta-adrenoceptors (beta1 and beta2) and alpha1-adrenoceptors, leading to decreased cardiac output, peripheral vascular resistance, and reduced blood pressure.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is: Intravenous: Initially 20 mg (0.25 mg/kg for 70 kg) over 2 minutes, then 40-80 mg every 10 minutes until desired response or total 300 mg; or continuous infusion at 0.5-2 mg/min titrated to blood pressure. Switch to oral when stable.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is classified as Category A/B. First trimester: Limited human data; animal studies show no major teratogenic effects at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.